In the trial, JCR’s Themcel HS Note” (human (allogeneic) bone marrow-derived mesenchymal stem cells) will be tested for effectiveness and safety in the treatment of epidermolysis bullosa. Epidermolysis bullosa is a hereditary severe rare disease that causes blisters and erosions by minor external forces on sites that are susceptible to external forces such as the periphery of the limbs and large joints.”
JCR Pharma news release, November 1, 2016
JCR Pharma and Osaka University Hospital in physician-led clinical trials on stem-cell therapy against epidermolysis bullosa